Related Experiment Videos
[Research on prognostic factors in large-cell lymphomas]
M A Gandarillas1, E Conde, F Mazorra
1Servicio de Hematología y Hemoterapia, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander.
Medicina Clinica
|April 29, 1995
Summary
Prognostic factors for large cell lymphoma (LCL) include general state (ECOG), Ann Arbor stage, and albumin. These variables help predict outcomes and can be used to create risk groups for better patient management.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Context:
- Large cell lymphomas (LCL) are aggressive non-Hodgkin lymphomas.
- Treatment strategies and prognostic factors for LCL require continuous evaluation.
- The International Prognostic Index (IPI) is a widely used tool for lymphoma prognostication.
Purpose:
- To identify prognostic factors in large cell lymphomas (LCL).
- To validate the International Prognostic Index (IPI) in a cohort of LCL patients.
- To develop a prognostic model for LCL based on factors at diagnosis.
Summary:
- A study of 124 newly diagnosed LCL patients treated between 1978-1990 analyzed prognostic factors.
- Key adverse prognostic factors for complete remission included advanced Ann Arbor stage, high tumor burden, and age ≥60.
- ECOG performance status ≥2, Ann Arbor stage, and hypoalbuminemia were independent adverse factors for overall survival.
Impact:
- Identified key variables (ECOG, Ann Arbor stage, albumin) for predicting LCL prognosis.
- Developed a prognostic model with three risk groups for LCL.
- Demonstrated the utility of the IPI in stratifying LCL patients into distinct prognostic groups.